EGFR/Axl dual inhibitors (Zhengzhou University)

N/A

Report date: 2026/05/13 20:02:10
NME

Base Information

Drug NameEGFR/Axl dual inhibitors (Zhengzhou University)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAXL receptor tyrosine kinase inhibitorsEpidermal growth factor receptor erbB1 inhibitors
TargetsEpidermal growth factor receptor erbB1AXL receptor tyrosine kinase
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesZhengzhou University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesZhengzhou University
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A